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Abstract 
Introduction: To evaluate the relationship between various biochemical, nutritional and demographic 
factors with immune response to hepatitis B vaccine in maintenance hemodialysis (HD) patients. 
Material and Methods: A retro-prospective study was carried out on 68 patients undergoing maintenance  
hemodialysis .Patients were vaccinated against hepatitis B virus with an intramuscular hepatitis B 
vaccination schedule, 40 micrograms at 0, 1, and 6 months. We also selected 32 age matched normal 
healthy persons who had vaccinated against hepatitis B previously to compare the antibody production 
with HD patients. Results: The value of serum antibody level against hepatitis B surface antigen ( HBs) in 
hemodialisis patients and healthy persons were 35±55(median=5.5) and 135±71 (median=175) mIU/ml 
respectively. There was a significant deference between mean serum antibody level against HBs antigen 
of hemodialysis patients and normal subjects (p<0.001), there were not any significant differences of 
antibody production against HBs antigen between males and females or diabetic and non diabetics. 
There were no correlation between serum antibody level against HBs-Ag and serum albumin and also 
with body mass index. There were not significant correlation between anti-HBs antibody level and age, 
amounts of hemodialysis, duration of dialysis, dialysis adequacy, serum ferritin level and serum lipids. 
There were not also significant correlation between anti-HBs antibody level and serum parathormone, 
calcium, phosphorus, serum hemoglobin and hematocrit level. Conclusion: In this study, there was not 
significant correlation between serum antibody level against hepatitis B surface antigen and various 
nutritional and demographic factors of patients under regular hemodialysis. 
Keywords: Hepatitis B; Hepatitis B vaccine; Hemodialysis; Malnutrition, Anti-HBs antibody. 
Introduction 
High susceptibility to various infections like hepatitis B virus (HBV) causes increased morbidity or 
mortality in patients with end stage kidney disease. HBV vaccination is recommended for all patients 
undergoing hemodialysis; however, antibody response is much lower than in healthy individuals [1]. In a 
study of 15 hemodialysis wards, it was found a serum hepatitis B surface antigen (HBs- Ag) prevalence 
of 16.8 percent in those patients [2]. It has been found that 30-40% of hemodialysis patients fail to 
produce antibodies against HBs-Ag antigen after vaccination towards hepatitis B virus [3]. Indeed 
hepatitis B vaccine response rates of 34-88% have been reported among hemodialysis patients [4], 
hemodialysis patients also have an inability to maintain adequate antibody titers during time [5]. The Azar BARADARAN  ,Mohammad-Reza ARDALAN, and Hamid NASRI 
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results of various studies showed that maintenance hemodialysis (HD) patients are at risk of 
malnutrition [6-8] which is associated with a reduced life expectancy mainly because of cardiovascular 
and infectious complications [6,10]. Protein-energy intake is often due to inappropriate dietary 
restrictions and anorexia which promot malnutrition in most patients under hemdialysis [8-13]. Because 
of the importance of accurately identifying hemodialysis patients capable of transmitting hepatitis B, we 
aimed to consider various biochemical, nutritional and demographic factors which could affect response 
to HBV vaccination in maintenance hemodialysis patients. 
Material and Method 
Patients 
This cross-sectional study was carried out on patients with end-stage renal failure (ESRD) 
undergoing maintenance HD with acetate basis dialysate and polysulfone membranes. The study was 
conducted in hemodialysis center of Hajar Medical, Educational and Therapeutic Center of Shahrekord 
in Iran in 2006 to 2007. 
According to the severity of the secondary hyperparathyroidism, each patient was under treatment 
for secondary hyperparathyroidism with oral active vitamin D3 (Rocaltrol), calcium carbonate, and 
Rena-Jel(sevelamer ) at various doses. According to the severity of anemia, patients were given 
intravenous iron sucrose (venofer) at varying doses after each dialysis session. All patients were also 
given folic acid 3 mg  daily, L-carnitine, 750 mg daily, B-complex tablets, and 2000 units of intravenous 
Eprex [recombinant  human erythropoietin (rHuEPO)] after each dialysis session routinely. Exclusion 
criteria were the presence of any active or chronic infection or using any antibiotics or NSAIDs and 
infection of hepatitis C virus. 
 In this study we also selected 32 ages matched normal healthy persons who had vaccinated against 
hepatitis B previously to compare the antibody production with HD patients. 
Hepatitis B Vaccination 
Patients’ vaccination was started before the study through a schedule of 0, 1, and 6 months. They 
received 2 ml (40μg) of Euvax Hbs-Ag ( hepatitis B recombinant vaccine which contains a preparation 
of the surface antigen of the  hepatitis B virus )  by intramuscular deltoid injections. Normal age 
matched  subjects were received from the same vaccine on a schedule of 0, 1, and 6 months and 4-5 
years had past from their last vaccinations. The local ethics committee approved the study and informed 
consent was obtained from all patients. 
Laboratory Methods 
Blood samples were collected after overnight fasting for complete blood count (CBC), levels of 
serum calcium (Ca), phosphorus (P), Alkaline phosphatase (ALP) iron, albumin (Alb), and ferritin 
[radioimmunoassay (RIA)] and also lipid profile were measured using standard methods. Intact serum 
parathormone (iPTH) was measured by the RIA method using DSL-8000 kits from the USA (normal 
range of values is 10-65 pg/ml).Antibodies to hepatitis B surface antigen (anti-HBs) were determined by 
the ELISA technique with Dialab kits (manufactured in Austria) at least 6 months after completion of 
initial vaccination series to assess response to vaccination. A subject had responded to the vaccine if the 
anti-HBS level was >10 mIU/ml. Those with levels 10–100 mIU/ml were termed ‘poor responders’, 
whereas those with levels >100 mIU/ml were termed ‘good responders’ [1].For measurement of 
adequacy of HD, urea reduction rate (URR) was calculated from pre- and post-blood urea nitrogen 
(BUN) data (14). .Duration and frequency of HD treatment were calculated from the patients' records. 
Body mass index (BMI) calculated using thestandard formula (post-dialysis weight in kilograms/ square 
height in meters, kg/m. The duration of each HD session was 4 hours. 
Statistical Analysis 
Data are expressed as the mean ± standard deviation (SD), median and range values. Comparison 
between the groups was performed using Student's t test. Statistical correlations were assessed using 
partial correlation test. All statistical analyses were performed using SPSS (version 11.5.00). Statistical 
significance was determined at p value < 0.05. Anti-Hbs-Ag in Stable Hemodialysis Patients
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Results 
Of 68 patients (female=19, male=49), 18 were diabetics.  
The mean age of the patients was 53 ± 18 years.  
The mean duration of patients on HD was 27 ± 29 months (Median: 22.8 months). 
Table 1, shows the parameters of the study patients.  
The mean value of antibody titer in hemodialisis patients and healthy persons were 35±55 
(median=5.5) and 135±71 (median=175) mIU/mL respectively (Table 1). 
Table 1. Data of the patients 
N=68  Range Median Mean±SD 
Age (year)  66  52  53±18 
DH (month)*  179  22.8  27±29 
Amounts of HD (numbers of dialysis) 4762  166.5  282±582 
BMI 25.3  22.4  22.7±4.4 
URR (%)  35  56  55.3±6.8 
Ca (mg/dl)  5  8.5  8.5±1.1 
P (mg/dl)  7.7  6.6  6.6±1.9 
IntactPTH (Pg/ml)  1457  204  322±311 
Alb  (g/dl)  1.6  3.8  3.7±0.4 
Hgb (g/dl)  5.8  18  10±2 
Hct %  27  32  33±5 
ALP(IU/l) 853  106  166±162 
Ferritin ng/dl  2145  699 688  ±499 
Iron micg/dl  1308  95 305±352 
Cholesterol (mg/dl)  54  150  150±54 
Tg (mg/dl)  454  104  136±83 
Anti-HBS 184  5.5  35±55 
*DH = duration of hemodialysis 
 
We did not find any significant differences of antibody production against hepatitis B   surface 
antigen between males and females or diabetic and non diabetics (p = N.S).  
Figure 1, shows that there was a significant deference between mean serum antibody level against 
hepatitis B surface antigen of hemodialysis patients  and normal subjects (r < 0.01). 
There was not significant correlation  between  serum albumin and serum antibody against hepatitis 
B surface antigen, also there were not any  significant correlation between anti-HBs  antibody level  with 
age, amounts of hemodialysis, duration of dialysis, BMI, URR, serum ferritin level  and serum lipids (p = 
N.S.). In this study  also there were not any  significant correlation between HBs  antibody level and 
serum iPTH, Ca, P, ALP, serum hemoglobin and hematocrit level too(p = N.S.). 
32 68 N =
r <0.001
1=hemodialysis,2=normal subjects
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Figure 1. Significant difference between mean serum antibody level against hepatitis B surface 
antigen and normal subjects (r<0.01) Azar BARADARAN  ,Mohammad-Reza ARDALAN, and Hamid NASRI 
 
70  Appl Med Inform 27(4) December / 2010
 
Discussion 
In this study we found  that there was a significant deference between mean serum antibody level 
against hepatitis B surface antigen of hemodialysis patients  and normal subjects, there were not  any 
significant differences of antibody production against  hepatitis B surface antigen  between  males and 
females  or diabetic and non diabetics. there was a significant deference between mean serum antibody 
level against HBs antigen of hemodialysis patients  and normal subjects(p<0.001), there were not  any 
significant differences of antibody production against HBs antigen between ales and females or diabetic 
and non diabetics. There were not correlation between serum antibody level against HBs-Ag and serum 
albumin and also with BMI. There were not significant correlation between anti-HBs antibody level and 
age, amounts of hemodialysis, duration of dialysis, dialysis adequacy, erum ferritin level and serum lipids. 
There were not also significant correlation between anti-HBs antibody level and serum parathormone, 
calcium, phosphorus, serum hemoglobin and hematocrit level. Patients with chronic kidney disease 
suffer from defective host defenses, which are directly the result of the renal impairment, in addition to 
those dependent on the primary illness leading to the renal failure [15]. Although vaccination can 
provide significant protection against hepatitis B virus infection, vaccine response rates are low and 
unpredictable among hemodialysis patients [5]. In adults with normal immune status, vaccine response 
rates are as high as 95%, and antibody to hepatitis B surface antigen (anti-HBs) remains above 
protective levels in 40-87% of persons for as long as 15 years. Only 34-88% of vaccinated hemodialysis 
patients develop protective levels of anti-HBs, and limited data are available that assess the persistence 
of this response [5]. Due to the impaired immune response, hemodialysis patients are given larger doses 
of the vaccine and frequently require revaccination or booster doses to produce and maintain adequate 
anti-HB titers [16-19].  Given the limited efficacy of hepatitis B vaccine in hemodialysis patients, it 
would be useful to identify factors that may influence vaccine response in these patients. Several studies 
have attempted to identify such factors. Previuos studies have shown that unresponsiveness to HBV 
vaccine is multifactorial, and related to the presence of several interacting factors.Studies showed that 
response rates were greatest among hemodialysis patients younger than 40 years [5] and   sex  may also 
influence vaccine response [20], however, other studies as well our results  have failed to show that sex 
or hemodialysis dose influence response to hepatitis B vaccine [5]. Ibrahim et al. [21] studied the 
evolution of HBsAg antibody (HBs-Ab) after primary vaccination in 29 HD patients and showed no 
significant correlation with age, duration of HD therapy, serum albumin. They found responders to 
primary vaccination had significantly higher levels of urea reduction ratio. They also showed the 
response to hepatitis-B vaccination among hemodialysis patients neither correlated with age, systemic 
inflammation nor nutritional status but efficient hemodialysis was associated with good response to 
hepatitis-B vaccine. Kara et al. in a retrospective study on 34 HD found, the immune response of the 
HBV vaccine was low in the HD patients and it was affected by several factors such as nutritional status 
[22]. Lombardi et al. [23] considered 35 HD patients who underwent anti-HBV vaccination and 
classified them to responders or non-responders. They evaluated the relationship of anthropometric and 
impedenziometric parameters with antibody production and found that these parameters were higher in 
responders than in non responders, but the difference did not reach statistical significance [23]. Dacko et 
al. [24] to find the factors contributing to the reduced antibody response to hepatitis B vaccination in 
peritoneal dialysis patients and the influence of nutritional status [as assessed by serum albumin] and 
dialysis adequacy on the development of hepatitis B antibodies examined 32 continuous ambulatory 
peritoneal dialysis/continuous cycling peritoneal dialysis patients. They found that patient age, sex, 
months on peritoneal dialysis, and race were not different among converters and nonconverters. Median 
serum albumin and final weekly Kt/V were not different among converters and nonconverters. They 
concluded that nutritional status, residual renal function, and weekly Kt/V in nutritionally replete and 
well-dialyzed peritoneal dialysis patients do not predict response to hepatitis B vaccine [24]. Fabrizi et al. 
[25] on 118 chronic HD patients who were received recombinant hepatitis B vaccine found a statistically 
significant difference between responder and non-responder patients with regard to nutritional 
parameters such as serum total proteins and mean levels of transferrinemia. They also found that the 
number of diabetic patients was significantly increased in the nonresponder group and also patients with 
persistent antibodies were younger and had a shorter duration of HD treatment compared to those 
responders who rapidly lost anti-HBs [25] . To identify factors implicated in the vaccine response, Peces 
et al. [26] conducted a study on vaccinated 80 seronegative patients on HD . The result of this study 
showed that there were no differences between responders and nonresponders concerning sex, time on Anti-Hbs-Ag in Stable Hemodialysis Patients
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HD, HD dose, nutritional status, hemoglobin level, HD membrane, iPTH level and calcitriol treatment 
(26). Kovacic et al. [27] conducted a study to see how dialysis efficacy affects response to hepatitis B 
virus (HBV) vaccination. Study subjects consisted of 30 patients on chronic haemodialysis. Subjects 
were divided into groups according to the level of HBsAb: non-responders and good responders. The 
group of responders had a significantly more efficient dialysis (Kt/V) than the group of non-responders. 
The group of good responders had a significantly better Kt/V than the group of non-responders. Kt/V 
values showed a significantly positive correlation with the HBs-Ab level. They concluded that HBV 
vaccination reaction was weaker in patients on chronic haemodialysis with inefficient dialysis. Efficient 
haemodialysis significantly improves the response to vaccination with recombinant HBs-Ag [27]. To 
assess if malnutrition influences the response to the hepatitis B virus vaccine Fernández et al. [1] 
considered sixty-four HD patients and found increase in age negatively influences the formation of 
antibodies, serum albumin and predialysis blood urea concentration are positively correlated with the 
formation of antibodies and responders had significantly higher levels of serum albumin and prealbumin 
and predialysis blood urea than non-responders. Patients with serum albumin levels between 3 and 3.5 
g/dl were non-responders in a higher percentage (87.5%) than those with serum albumin levels between 
4.5 and 5 g/dl (18.8%). Authors concluded that malnutrition negatively influences the response to the 
hepatitis B virus vaccine in haemodialysis patients [1]. Very recently Ocak et al. [28] to investigate 
whether haemodialysis patients who  suffering from diabetes mellitus could be considered at risk for the 
development of the protective antibodies to hepatitis B  vaccination conducted a study on  forty-nine 
HD patients  which  were divided into two groups: group A (19 diabetic patients) and group B (30 non-
diabetic patients), after vaccination group A found to have a lower protective antibody rates than the 
patients in group B .They  showed that diabetic patients on HD may carry a greater risk of not 
seroconverting than non-diabetic ones for antibody response to HB vaccination [28]. Sorkhi et al. in a 
study on 62 HD patients showed duration of haemodialysis had no effect on response to vaccination 
[29]. In an another study conducted by Ramezani et al. [30] on 54 HD patients could not found any 
correlation between anti-HBs titers and serum hemoglobin, serum albumin, triglycerides, cholesterol, 
fasting blood sugar, PTH, efficiency of dialysis, duration of dialysis treatment, sex, smoking, percentage 
of subjects with DM. They concluded that unresponsiveness to HBV vaccine is multifactorial, and 
related to the presence of several modulators [30].  
Conclusions 
This study was designed to examine the relationship between various biochemical, nutritional and 
demographic factors with immune response to hepatitis B vaccine in maintenance hemodialysis (HD) 
patients. We could not show any significant correlation between serum antibody level against hepatitis B 
surface antigen and various nutritional and demographic factors of patients under regular hemodialysis. 
However, previous authors showed different results, some of them were in accordance with our study. 
We concluded that factors related to serum antibody level against hepatitis B surface antigen were 
different in this group of patients and different factors might be responsible for antibody production 
and more multicentre studies need to clearly define  these related factors.  
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